Xcout Intel
BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Subscribe to see BridgeBio Pharma, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
BridgeBio Pharma, Inc. at a glance
BridgeBio Pharma, Inc. is a biopharmaceuticals company headquartered in Palo Alto, United States, founded in 2015. It is publicly listed (BBIO) with a market capitalisation of $13.3B. Xcout tracks 24 named people at BridgeBio Pharma, Inc., including Eric Michael David (Chief Executive Officer of Gene Therapy).
BridgeBio Pharma, Inc. leadership
- Eric Michael DavidChief Executive Officer of Gene Therapy
- Thomas TrimarchiChief Financial Officer & President
- Uma SinhaChief Scientific Officer
- Eli WallaceChief Scientific Officer of Oncology
- Maricel ApuliChief Accounting Officer
- Matthew OuttenChief Commercial Officer
18 more named people on record for BridgeBio Pharma, Inc., with roles, board committees and tenure — see the full roster →
Hiring at BridgeBio Pharma, Inc.
Tools named in BridgeBio Pharma, Inc.'s job postings
The weekly hiring trend, the roles and locations behind it — see BridgeBio Pharma, Inc.'s hiring signals →
Tech stack
BridgeBio Pharma, Inc. competitors
A few of BridgeBio Pharma, Inc.'s closest competitors — see the full list of competitors and alternatives →
Bridge Medicines LLC is a drug discovery holding company headquartered in New York, NY, that accelerates the path of therapeutic pipelines from research to patients.
Bend Bioscience is a U.S. pharmaceutical contract development and manufacturing organization (CDMO) dedicated to advancing pharmaceutical innovation. It offers design, development, and manufacturing services ranging from early formulation to commercial-scale production.
Avidity Biosciences, Inc. is a biopharmaceutical company dedicated to delivering a novel class of RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs) to profoundly improve people's lives. Headquartered in San Diego, California, the firm focuses on advancing precision genetic medicines for various diseases. As of February 2026, the company operates as a subsidiary of Novartis.
Enlaza Therapeutics, Inc. is a biotechnology enterprise headquartered in California, United States. The company designs and develops next-generation covalent biologic therapeutics targeting serious diseases. It utilizes specialized proprietary discovery platforms to advance precision medicine applications.
Allena Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Newton, Massachusetts, focused on the research, development, and commercialization of orally administered enzyme therapeutics for rare and severe metabolic and kidney disorders.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Get BridgeBio Pharma, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on BridgeBio Pharma, Inc. in Xcout Intel
- 24 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access